跳至主要内容
临床试验/NCT03052569
NCT03052569No Longer Available不适用

Expanded Access to RXDX-105 for the Treatment of Cancers With RET Alterations

Hoffmann-La Roche1 个研究点 分布在 1 个国家开始时间: 2017年2月14日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
No Longer Available
试验地点
1

研究概览

简要总结

Expanded access to RXDX-105 will be given to patients with cancers harboring RET alterations who have not received TKIs that target RET alterations, who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for RXDX-105.

研究设计

研究类型
Expanded Access

入排标准

性别
All
接受健康志愿者

入选标准

  • Diagnosis of advanced cancer with RET alterations
  • Unable to participate in an ongoing RXDX-105 clinical trial
  • Willing and able to provide written, signed informed consent
  • Medically suitable for treatment with RXDX-105

排除标准

  • Prior treatment with a TKI that has activity against RET alterations
  • Currently enrolled in an ongoing clinical study with any other investigational agent

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验